Calu-6 Human Non-Small Cell Lung Adenocarcinoma Model

Author: Gunisha Arora, PhD, Medical and Scientific Writer, Scientific Development
Date: August 2025

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases.¹ Among its subtypes, adenocarcinoma is the most prevalent, often diagnosed at advanced stages due to its asymptomatic progression. The complexity of lung cancer, characterized by diverse histological subtypes and genetic mutations, presents significant challenges for effective therapeutic intervention and highlights the urgent need for robust preclinical models to unravel disease mechanisms and develop novel, more effective treatments. The Calu-6 cell line has emerged as a widely studied and well-characterized model in lung cancer research.²

Originally derived from the pleural effusion of a 61-year-old female patient with anaplastic lung carcinoma, Calu-6 cells exhibit epithelial morphology and harbor key genetic alterations, including KRAS codon 61 mutation and TP53 inactivation.^2,3 This makes it particularly valuable for research into KRAS-driven lung cancers, which are often resistant to conventional therapies and targeted treatments. When grown in vivo as subcutaneous (SC) xenografts in immunocompromised mice, Calu-6 cells form poorly differentiated carcinomas that mimic aspects of human lung adenocarcinoma, providing a more complex microenvironment for evaluating anti-tumor efficacy.⁴  

At Labcorp, we have run several studies using the Calu-6 model of human NSCLC in the subcutaneous setting in female nude mice with multiple standard agents and vehicles. This model has shown reproducible growth across different studies with progressive weight gain.

Growth Kinetics
 

Figure 1. Growth kinetics of subcutaneously implanted Calu-6 tumors. Mean tumor burden (mm3) ± SE on the top left, percent body weight change ± SE on the top right and individual tumor growth curves on the bottom left.
 

Responses to Treatments

To establish a baseline for comparing treatment outcomes and providing a framework for integrating standard of care (SoC) responsiveness into future preclinical efficacy studies, therapeutic response and tolerability of different agents were assessed in the SC Calu-6 tumor model. Chemotherapies, focal radiation and targeted therapies including anti-angiogenic agents and checkpoint inhibitors were used to establish this model’s SoC profile. 

Figure 2. Efficacy of multiple SoC agents targeting subcutaneously implanted Calu-6 tumor model. Mean tumor burden (mm3) ± SE on the left and percent body weight change ± SE on the right. 
 

Figure 3. Individual tumor growth curves for each SoC agent, displayed in comparison to the control group.
 

Characterized by its tumorigenic potential in xenograft models, stable growth characteristics and responsiveness to various therapeutic agents, Calu-6 makes a valuable model for investigating oncogenic signaling pathways, drug resistance mechanisms and the efficacy of novel anti-cancer compounds in KRAS-driven NSCLC.

For other lung cancer models, check out our cell line list.